Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase
- First Online:
- Cite this article as:
- Tappe, D., Pérez-Girón, J.V., Zammarchi, L. et al. Med Microbiol Immunol (2016) 205: 269. doi:10.1007/s00430-015-0445-7
- 5.8k Downloads
Zika virus is an emerging mosquito-borne flavivirus currently causing large epidemics in the Pacific Ocean region and Brazil. Clinically, Zika fever resembles dengue fever, but is less severe. Whereas the clinical syndrome and laboratory diagnostic procedures have been described, little attention was paid to the immunology of the disease and its possible use for clinical follow-up of patients. Here, we investigate the role of cytokines in the pathogenesis of Zika fever in travelers returning from Asia, the Pacific, and Brazil. Polyfunctional T cell activation (Th1, Th2, Th9, and Th17 response) was seen during the acute phase characterized by respective cytokine level increases, followed by a decrease in the reconvalescent phase.
KeywordsZika virus Arbovirus Flavivirus Zika fever Outbreak Cytokine
Zika virus (ZIKV), a mosquito-borne flavivirus, has lately come to international attention owing to outbreaks on Yap Island, Federated States of Micronesia, in 2007  and in French Polynesia beginning in 2013 , and a current epidemic after its recent introduction to Brazil . Both epidemics have been attributed to the Asian genotype of ZIKV [2, 3], likely introduced by viremic travelers. The virus is maintained in a natural cycle involving non-human primates and various Aedes mosquito species . ZIKV causes a self-limiting, dengue fever (DF)-like disease with an incubation time of up to 10 days. Signs and symptoms consist of rather low-grade fever, myalgia and a maculopapular rash, accompanied by arthralgia and headache, and less often edema, sore throat, and vomiting [1, 2, 3, 4]. In contrast to DF, acute Zika fever (ZF) is less severe; headache and malaise are less intense and haemorrhagic and shock complications have not been reported. Conjunctivitis is often present, whereas arthralgia is less pronounced . However, unusual rates of Guillain Barré syndrome (GBS) were reported in French Polynesia due to ZIKV infection . Laboratory changes include transient leukopenia and in some cases thrombocytopenia. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations may or may not be elevated . Travel-associated infections from both endemic ([6, 7] as examples) and epidemic areas [8, 9] have been documented in non-endemic countries, including the recent report of a patient seen in Italy who became infected in Salvador de Bahia state, Brazil, in the current evolving outbreak.
Whereas the clinical syndrome and laboratory diagnostic procedures, including generic and real-time reverse transcription polymerase chain reactions (RT-PCRs) as well as specific non-commercial serology tests and cross-reactions have been described, little attention was paid to the immunology of the disease and its putative use for clinical follow-up of patients. Here, we analyzed serum cytokine levels of travel-associated infections and demonstrate cytokine concentration changes in acute and recovery (reconvalescent) sera. These changes suggested that strong and multifunctional T cell responses are required for recovery from ZIKV infection.
Patients and methods
Characteristics of patients infected with Zika virus included in the study
Serum taken after disease onset (days)
Tappe et al. 
35 and 62
Zammarchi et al. 
Zammarchi et al. 
5 and 10
Tappe et al. 
4 and 26
Zammarchi et al. 
No significant changes, neither in the acute nor in the recovery phase, could be observed for IL-1ra, IL-5, IL-7, IL-12, monocyte chemotactic protein 1 (MCP-1), eotaxin, and platelet-derived growth factor-bb (PDGF-bb; data not shown). There were no significant changes between any of the cytokine levels measured in the acute versus the recovery phase.
In contrast to the clinically similar DF, acute ZIKV infections are less severe and secondary infections are not described owing to the fact that only one serotype of ZIKV exists. After an acute ZIKV infection immunity to re-infection is established for an unknown time span, based on epidemiological evidence from past outbreaks [1, 2]. In the patients studied here, elevation of chemokines was more pronounced than elevation of cytokines. In the recovery phase, cytokine levels generally decreased. A polyfunctional immune activation was seen during the acute phase of ZF, as reflected by elevated cytokine profiles associated with Th1 (IL-2, and non-significantly IFN-γ), Th2 (IL-4, IL-13), Th17 (IL-17), and also Th9 (IL-9) responses. Data on IL-9 functions during human viral infection is scarce, but studies have shown an association of elevated IL-9 levels and severe acute respiratory syncytial virus infections  and non-response to treatment of chronic hepatitis C , suggesting a modulator role of antiviral immunity. In our study, IL-2, IFN-γ and TNF-α levels were surprisingly lower than expected, contrasting with findings in other arboviral infections [12, 13]. Of note, in our study RANTES is already increased in the acute phase, whereas IP-10 is particularly elevated in the recovery phase. Effective T cell recruitment to infection sites and formation of effector T cells was suggested by both increased RANTES and IP-10 concentrations [14, 15]. Since CCR5 and CxCR3 are chemokine ligands receptors for RANTES and IP-10, respectively, immunophenotyping of peripheral blood T cells of ZIKV-infected patients as well as functional T cell assays should help to further explore the role of RANTES and IP-10 during ZF. Similar to descriptions of patients infected with dengue virus (DENV) , a related flavivirus, sera of patients with ZF analyzed in our study also showed increased IL-4, IL-6, IL-8, IL-10, and IP-10 levels. IL-10 levels were also highest in the later (recovery) phase of ZIKV infection, as seen in DF . In contrast to DF, however, concentrations of IL-1ß, IL-2, MCP-1, and VEGF were not decreased in ZF patients. In DF, elevated IL-8 and IL-10 levels were shown to be associated with severe infection , a clinical state which has so far not been seen in ZF. No “cytokine storm effects”, as known from DENV infections  were demonstrated in the ZF patients in our study. Of note, significantly increased IFN-γ and TNF-α levels were absent in ZF in contrast to DF, pointing toward a Th2 bias in ZIKV infections. In DENV infections, thrombocytopenia correlated strongly with RANTES and VEGF levels . Both RANTES, a chemokine stored in a-granules of platelets, secreted upon platelet activation, and VEGF, a growth factor released by platelets, would be expected to decrease upon thrombocytopenia. In contrast, severe thrombocytopenia is rarely observed in ZF patients and RANTES and VEGF did not show decreased levels when compared with the control group. It remains to be elucidated whether ZIKV-induced GBS  might be associated with different cytokine responses than changes in non-GBS ZIKV-infected patients.
Due to the small number of ZF patients examined, this study and the strength of the observations are limited. We have analyzed cytokine levels over time in returning travelers to Europe, and it is unknown whether different human ethnic groups might show different cytokine responses as described for DF . Recent ZF epidemics were only caused by the Asian genotype of ZIKV, which is the same genotype also seen in travel-related infections from outbreak areas. Thus, the cytokine data presented here are linked to an infection with the Asian genotype. As a restriction of the study, functional T cell tests (i.e., stimulation with ZIKV antigen followed by intracellular cytokine staining) have not been performed. Future studies will address lymphocyte and cytokine responses in more detail, allowing proper conclusions of Th1- and Th2-biased cell responses. Despite showing rather preliminary data, to our knowledge, this is the first study investigating immune parameters in acute ZF.
Compliance of ethical standards
Conflict of interest
All authors declare that they have no conflicts of interest. No author has a commercial or other association that might pose a conflict of interest (e.g., pharmaceutical stock ownership, consultancy, advisory board membership, relevant patents, or research funding).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.